Starling Oncology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Starling Oncology, Inc. (DFPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Starling Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- Starling Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $2.00 10-Q · filed 2025-11-13 | ||
| 2023-09-30 | $0.48 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.48 10-Q · filed 2023-08-09 | ||
| 2022-09-30 | $7.14 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $7.14 10-Q · filed 2023-08-09 |